Clinical studies support that plasma measures of GFAP correlate with its CSF levels and are increased in CU individuals with AD pathophysiology, representing a robust proxy of astrocyte reactivity in the brains of these individuals21–24. This evidence concerns the gene GFAP and Alzheimer disease.